Home R&D/Pipeline overview>
Latest News
See all news

R&D

Pipeline overview

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our Target Discovery Program aims at discovering and developing novel immuno-oncology antibody candidates, including novel immune checkpoint inhibitors and other immunological targets. OREGA biotech integrates translational science insights to select the right immunology targets and advances programs that leverage contributions from its experienced academic founders as well as knowledge acquired from OREGA’s Target Discovery Platform to achieve rapid target validation and preclinical proof-of-concept.

 

The R&D programs are performed in the laboratories located at the Institut de Recherche en Cancérologie of Montpellier and at the Hôpital Saint-Louis in Paris as well as within our network of academic collaborators and industrial partners. 

 

With a specific focus on tumor microenvironment, the current pipeline encompasses monoclonal antibodies targeting CD39, a novel immune checkpoint and cancer-related inflammation.

 

 

 

 

 

Events
See all events